Global Search

Search articles, concepts, and chapters

Curr Opin OphthalmolDecember 200331 citations

Neuroprotection in glaucoma: a model for neuroprotection in optic neuropathies.

Marcic Tania Sibila, Belyea David Anthony, Katz Barrett


AI Summary

This review highlights glaucoma as an ideal model for neuroprotection studies, crucial because IOP reduction isn't always sufficient, emphasizing preserving retinal ganglion cells to prevent vision loss.

Abstract

Purpose of review: Efforts to discover modalities and pathophysiologies that might afford successful neurorescue, neurorestoration, and neuroprotection of cells of the central nervous system have focused on processes that affect the central nervous system proper, that is, the brain. Often overlooked in the search for neural protection is the fact that the mammalian optic nerve behaves in many ways as an integral part of the central nervous system. As such, the eye--the optic nerve and retina--affords an ideal clinical model for neuroprotection and neuroprotective agents. Glaucomatous optic neuropathy is the most prevalent of all adult optic neuropathies, and offers an ideal primate and lower mammalian animal model for investigations of neuroprotection.

Recent findings: This is especially compelling because while recent studies in glaucoma have shown reduction of intraocular pressure (IOP) to be an effective modality in the treatment of glaucomatous optic neuropathy, not all patients respond to or can achieve meaningful IOP reductions. Therefore much attention has now been focused on neuroprotection as a strategy in therapies for glaucomatous optic neuropathy as a means of preserving retinal ganglion cells and their axonal projections.

Summary

This review discusses the latest studies on various mechanisms of neuroprotection in the treatment of glaucomatous optic neuropathy.


MeSH Terms

AnimalsCaspase InhibitorsEnzyme InhibitorsExcitatory Amino Acid AntagonistsGlaucomaHumansNerve Growth FactorsNeuroprotective AgentsNitric Oxide SynthaseNitric Oxide Synthase Type IIOptic Nerve DiseasesTumor Necrosis Factor-alphaVaccines

Is this article assigned to the wrong chapter(s)? Let us know.